Mast cells in atherosclerosis as a source of the cytokine RANKL

被引：30

作者：

Ali, Ahmed Salem

Lax, Anna-Satina

Liljestrom, Mikko

Paakkari, Ilari

Ashammakhi, Nureddin

Kovanen, Petri T.

Konttinen, Yrjo T.

机构：

[1] Univ Helsinki, Inst Biomedicum, Dept Anat, FIN-00014 Helsinki, Finland

[2] Garyounis Univ, Dept Pediat Dent, Fac Dent, Benghazi, Libya

[3] Univ Helsinki, Inst Biomed, Dept Pharmacol, FIN-00014 Helsinki, Finland

[4] Oulu Univ Hosp, Dept Surg, Oulu, Finland

[5] Tampere Univ Technol, Inst Biomat, FIN-33101 Tampere, Finland

[6] Wihuri Res Inst, SF-00140 Helsinki, Finland

[7] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland

[8] Invalid Fdn, ORTON Orthoped Hosp, Helsinki, Finland

[9] COXA Joint Replacement Hosp, Tampere, Finland

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2006年 / 44卷 / 05期

关键词：

arterial calcification; atherosclerosis; mast cells; RANKL;

D O I：

10.1515/CCLM.2006.117

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：672 / 674

页数：3

共 10 条

[1] Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J].

Dhore, CR ;

Cleutjens, JPM ;

Lutgens, E ;

Cleutjens, KBJM ;

Geusens, PPM ;

Kitslaar, PJEHM ;

Tordoir, JHM ;

Spronk, HMH ;

Vermeer, C ;

Daemen, MJAP .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (12) :1998-2003

[2] Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease [J].

Hansson, GK .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (16) :1685-1695

[3] Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries [J].

Jeziorska, M ;

McCollum, C ;

Woolley, DE .

VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1998, 433 (06) :559-565

[4] ACCUMULATION OF ACTIVATED MAST-CELLS IN THE SHOULDER REGION OF HUMAN CORONARY ATHEROMA, THE PREDILECTION SITE OF ATHEROMATOUS RUPTURE [J].

KAARTINEN, M ;

PENTTILA, A ;

KOVANEN, PT .

CIRCULATION, 1994, 90 (04) :1669-1678

[5] Atherosclerosis [J].

Lusis, AJ .

NATURE, 2000, 407 (6801) :233-241

[6] Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis [J].

Min, H ;

Morony, S ;

Sarosi, I ;

Dunstan, CR ;

Capparelli, C ;

Scully, S ;

Van, G ;

Kaufman, S ;

Kostenuik, PJ ;

Lacey, DL ;

Boyle, TJ ;

Simonet, WS .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :463-474

[7]

SAARINEN J, 1994, J BIOL CHEM, V269, P18134

[8] Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men [J].

Schoppet, M ;

Schaefer, JR ;

Hofbauer, LC .

CIRCULATION, 2003, 107 (11) :E76-E76

[9] RANK ligand and osteoprotegerin - Paracrine regulators of bone metabolism and vascular function [J].

Schoppet, M ;

Preissner, KT ;

Hofbauer, LC .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) :549-553

[10] Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure [J].

Ueland, T ;

Yndestad, A ;

Oie, E ;

Florholmen, G ;

Halvorsen, B ;

Froland, SS ;

Simonsen, S ;

Christensen, G ;

Gullestad, L ;

Aukrust, P .

CIRCULATION, 2005, 111 (19) :2461-2468

← 1 →